Novolog (Pharm-Up 1966) Ltd

Tel Aviv Stock Exchange NVLG.TA

Novolog (Pharm-Up 1966) Ltd EBT Margin for the year ending December 31, 2023: 0.11%

Novolog (Pharm-Up 1966) Ltd EBT Margin is 0.11% for the year ending December 31, 2023, a -97.83% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Novolog (Pharm-Up 1966) Ltd EBT Margin for the year ending December 31, 2022 was 4.85%, a -1.44% change year over year.
Novolog (Pharm-Up 1966) Ltd EBT Margin for the year ending December 31, 2021 was 4.92%, a 6.21% change year over year.
Novolog (Pharm-Up 1966) Ltd EBT Margin for the year ending December 31, 2020 was 4.63%, a 153.36% change year over year.
Novolog (Pharm-Up 1966) Ltd EBT Margin for the year ending December 31, 2019 was 1.83%, a -45.38% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Tel Aviv Stock Exchange: NVLG.TA

Novolog (Pharm-Up 1966) Ltd

CEO	Mr. Aviad Bossi
IPO Date	Feb. 28, 2017
Location	Israel
Headquarters	55 HaMaayan Street
Employees	955
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.

Key trends

Past 5 years